Skip to Content
Morningstar
Get 14 Days Free

Charles River Laboratories International Inc CRL

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Charles River Reports Strong Q4 Results and Acquisition of Cognate BioServices; Raising FVE to $161

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Charles River announced fourth-quarter revenue of $791 million, ahead of our and FactSet’s consensus expectations, driven by 10.3% organic revenue growth and full-year revenue of $2.9 billion, growing 11.5% from the prior year. Full-year GAAP operating margin increased 140 basis points to 14.8% due to efforts to drive operating efficiency and temporary cost reductions related to COVID-19.

Read Full Analysis

Company Profile

Business Description

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.

Contact
251 Ballardvale Street
Wilmington, MA, 01887
T +1 781 222-6000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 18,400

Related

Stock Strategist Industry Reports
Late-Stage Businesses Drive Narrow Moats for CROs
The top contract research organizations have opportunities to gain share in a rapidly growing industry.
David Krempa
Stock Strategist
M&A Market Awaits Clearer Economic Signals
The means and motives for deals are in place, but macroeconomic fears will likely keep the M&A market in waiting.
R.J. Hottovy
Stock Strategist Industry Reports
Strengthening Moats Mean Improving Returns for CRO Investors
The contract research organization industry's recovery is finally making its way into earnings and valuations.
Lauren Adams
Commentary
These Stocks Are Gifts That Could Keep on Giving
Despite a big runup in 2012, shares in these firms still look attractively priced.
Jeremy Glaser
Stock Strategist Industry Reports
Buy One, Get One Free at Charles River Laboratories
The current stock price assigns almost no value to this top-tier CRO's preclinical services segment.
Lauren Adams
Stock Strategist Industry Reports
CROs Will Return to Relevance in 2012
Contract research organizations remain on sale as industry rebound gains steam.
Lauren Adams
Stock Strategist Industry Reports
CROs Still On Sale as Industry Begins Rebound
Market uncertainty has uncovered opportunity in this high-growth sector.
Lauren Adams
Premium Article
More Picks for the Pullback
Hoping to buy on the dip? These stocks are a good place to look.
Jeremy Glaser
Premium Article
Picks for the Pullback
Looking to buy on the dip? These stocks are a good place to look.
Jeremy Glaser
Stock Strategist Industry Reports
Data Points Show CROs on the Brink of Recovery
Despite bookings improvement, firms continue to trade below fair value.
Lauren Adams
Stock Strategist Industry Reports
CRO Investment Opportunities Remain Compelling
Near-term demand remains choppy, but bookings growth shows CRO model promise.
Lauren Adams
Quarter-End Insights
Our Outlook for Health-Care Stocks
Mergers and acquisitions replace reform as a key health-care topic.
Alex Morozov
Stock Strategist Industry Reports
CROs Close out Tough 2010
Slow growth persists among CROs, but we see a rebound on the horizon.
Lauren Adams
Stock Strategist Industry Reports
We Expect Ailing CROs to Recover
The near-term environment remains tough, but we're bullish on the CROs' long-term prospects.
Lauren Adams
Stock Strategist Industry Reports
Is It Time to Test Contract Research Organizations?
Despite near-term challenges, we think contract research providers are set for long-run gains.
Jeffrey Stafford
US Videos
An Opportunity Worth Testing
Stock in this lab research-services firm has been beaten down too far.
Justin Perucki
Quarter-End Insights
Our Outlook for Health-Care Stocks
Market challenges the defensive nature of health care.
Alex Morozov
Stock Strategist
Democrat-Proof Health-Care Stocks
Despite changing political winds, we're still bullish on these five firms.
Karen Andersen
Stock Strategist
A Stable Niche in Big Pharma
CROs can offer safety in an explosive industry.
Emil Lee
Fund Spy
Baron Funds Conference 2002
Baron is bullish on stocks, but continues to avoid tech stocks.
Christopher Traulsen